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Abstract
Objective The safety and efficacy of surgical microvascular decompression (MVD) in elderly patients with trigeminal neu-
ralgia (TN) is controversially discussed in the literature. A widespread reluctance to expose this cohort to major intracranial 
surgery persists. Our aim was to compare the efficacy and safety between older and younger patients with TN.
Methods In this cross-sectional study, 139 MVD procedures (103 patients < 70 and 36 patients ≥ 70) were included. Surgical 
fitness was assessed by the American Society of Anesthesiology (ASA) grade. The pain-free interval was evaluated using 
Kaplan–Meier analysis only in patients with a recent follow-up visit. Independent risk factors for recurrence in patients with 
a minimum 12-month follow-up were determined.
Results Patients ≥ 70 showed a significantly higher number of comorbidities. Pain intensity, affection of trigeminal branches 
and symptom duration was similar between groups. No significant difference in treatment associated complications and per-
manent neurological deficits was shown. There was no treatment-related mortality. A tendency towards a lower recurrence 
rate in patients < 70 did not reach statistical significance (17.6% vs. 28.6%, P = 0.274). Pain-free interval was not different 
between both cohorts (78.7 vs. 73.5 months, P = 0.391).
Conclusion Despite a higher prevalence of comorbidities in elderly patients, complication rates and neurological deficits after 
MVD were comparable to younger patients. Rates of immediate and long-term pain relief compared favorably to previous 
studies and were similar between elderly and younger patients. These data endorse MVD as a safe and effective first-line 
surgical procedure for elderly patients with TN and neurovascular conflict on MRI.
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Introduction
Classical trigeminal neuralgia (TN) is a chronic pain disor-
der manifesting with unilateral paroxysmal stabbing pain 
involving one or more divisions of the trigeminal nerve. It 
is the most prevalent facial pain syndrome and pain onset is 
usually between the ages of 40 and 60. Pain severity can hin-
der activities of daily living and impairs quality of life [26].
Anticonvulsant medication is the first-line therapy and 
can reduce TN pain intensity in 75% of patients [10]. 
However, the efficacy of conservative treatment generally 
decreases over time and TN is frequently resistant to multi-
drug treatment regimens. Also, these medications commonly 
induce side effects that lead to discontinuation of the medi-
cal therapy [39].
Around 75% of TN cases are associated with trigeminal 
nerve compression by a branch of the superior cerebellar 
artery or other blood vessels [2, 8, 12]. In cases where such 
a neurovascular conflict is present and where other underly-
ing etiologic conditions such as demyelinating autoimmune 
diseases are ruled out, microvascular decompression of the 
trigeminal nerve (MVD) is the primary surgical treatment 
option since it is the only causal treatment for TN and offers 
a high rate of immediate and long-term pain relief [14, 15].
Although MVD is widely offered to younger patients, 
neurosurgeons tend to be reluctant to offer MVD to elderly 
patients, primarily because of concerns regarding complica-
tions of general anesthesia and posterior fossa surgery [3, 
19, 21, 31].
However, the incidence of TN increases with age, with 
4.1 per 100,000 per year in the general population [9, 20] 
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and 20 per 100,000 per year in patients above 65 years [1]. 
Antiepileptic drugs used to treat TN induce side effects more 
frequently in elderly patients [39] and these patients are gen-
erally more sensitive to disturbances of the central nervous 
system, which can result in gait disturbances and ataxia and 
an increased tendency to fall [34]. In addition to possible 
comorbidities, there are physiological changes during aging, 
which render the serum concentration of antiepileptic drugs 
unpredictable [29]. One study found 25% of patients taking 
more than one drug were possible candidates for drug–drug 
interactions in the geriatric cohort [37]. Older patients are 
more often offered symptomatic surgical therapies such as 
percutaneous balloon compression [4] or radiofrequency 
rhizotomy [17] which access the gasserian ganglion via the 
oval foramen and circumvent the need for major intracranial 
neurosurgery. These symptomatic surgical options are how-
ever associated to poorer long-term pain control compared 
to MVD [24].
A higher incidence of TN in the elderly and the above-
mentioned clinical particularities in this cohort combined 
with an overall ageing society [7] warrant a new perspective 
on MVD for patients in the senium.
The purpose of this study was to analyze the neurologi-
cal outcome and TN recurrence rates in patients beyond 
70 years of age in comparison to younger patients to add 
more definitive data to the mixed reports on that topic.
Methods
Study design
In this single-center cross-sectional study, we reviewed the 
medical records of 485 consecutive patients undergoing 
surgical procedures to treat trigeminal neuralgia between 
01/2012 and 02/2020. Patients who only received radiofre-
quency rhizotomy and who previously received MVD were 
excluded. Absence of a neurovascular conflict on MRI, pres-
ence of tumors within the proximity of the trigeminal nerve 
and presence of demyelinating autoimmune diseases were 
excluded. Whether the neurovascular conflict was specific 
to the root entry zone or whether the nerve showed atro-
phy was not evaluated. Consequently, a possible change in 
outcome depending on these MRI parameters was not part 
of the study. To comply with the cross-sectional design of 
the study, all remaining patients were actively contacted 
and only those who were followed up within 4 weeks of the 
study end (database closure 03/2020) were included. By this 
means, 139 MVD procedures (equaling 139 patients) were 
included (Fig. 1). The study duration for each patient ended 
upon recurrence or with the most recent follow-up. The local 
ethics committee board approved this cross-sectional analy-
sis (approval number 20-233). Patient consent was waived 
for this study. Patients younger than 70 years of age at 
Fig. 1  Schematic overview of 
patient inclusion and exclusion
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surgery (termed thereafter “patients < 70”) and patients that 
were 70 years or older (termed thereafter “patients ≥ 70”) 
were compared using.
Preoperative decision‑making and operative 
technique
All patients < 70 with TN and a visible neurovascular con-
flict were recommended to undergo MVD when conserva-
tive management was insufficient to control pain or when 
significant side effects of the medication were reported. In 
patients < 70 who showed relevant comorbidities, who did 
not show a neurovascular conflict or who had a history of 
an inflammatory demyelinating disease, radiofrequency rhi-
zotomy was recommended as an alternative surgical option 
for TN.
Patients ≥ 70 were routinely recommended radiofre-
quency rhizotomy but were also offered to undergo MVD 
when American Society of Anesthesiology (ASA) grade was 
3 or less.
Microvascular decompression was performed via a ret-
rosigmoid approach with the patient in a modified park 
bench position. Intraoperative monitoring was performed in 
all cases. Patients were usually seen in the outpatient clinic 
for the first follow-up examination after 3 months.
Analysis and outcome definitions
TN disease variables included degree of pain intensity meas-
ured by the numerical rating scale (NRS) [13, 23], degree 
of pain control with/without medication measured by the 
Barrow Neurological Institute Pain Intensity (BNI) Score 
[30], TN medication regimen before MVD and duration 
of TN symptoms before MVD. The operative fitness sta-
tus was assessed by the ASA grade [11] and by identifying 
comorbidities.
Postoperative data included length of hospital stay, pres-
ence of neurologic deficits, pain intensity before and after 
MVD, oral pain medication before MVD and after MVD, 
complications and subsequent TN procedures. Pain intensity 
was determined at the first follow-up and at the most recent 
follow-up visit or most recent follow-up telephone interview 
using NRS rating and BNI Score.
Statistics
We used Fisher’s exact test and Chi-square test with Yates 
correction to compare distribution of categorical variables 
among groups. Continuous variables were tested for normal 
distribution using the Shapiro–Wilk test and no continuous 
variable was found to be normally distributed. Consequently, 
we employed Mann–Whitney U test to compare continuous 
variables.
Long-term pain intensity and outcome were only per-
formed in patients who either suffered a recurrence or who 
had a follow-up period of at least 12 months. Long-term out-
come was evaluated by Kaplan–Meier analysis with log-rank 
testing to compare the pain-free interval between groups. 
Binary logistic regression analysis was employed to find fac-
tors associated with recurrence. Statistical significance was 
set at P < 0.05. All statistical analyses were performed using 
SPSS version 25 (IBM).
Results
Demographics and characterization of trigeminal 
neuralgia
Of 139 patients with TN who received an MVD, 103 (74.1%) 
were younger than 70 years and 36 (25.9%) were 70 years 
or older. The age difference was statistically different as 
per definition of both patient cohorts (P < 0.001). Absolute 
numbers of risk factors for TN like additive headache syn-
dromes, chronic sinusitis or previous sinus surgery were low 
and similar in both groups. There was a significantly higher 
proportion of hypercholesterolemia, arterial hypertension, 
carotid stenosis, and history of cancer in patients ≥ 70. Other 
comorbidities were not different between groups (Table 1). 
As a composite score of preoperative comorbidities, the 
above-mentioned differences reflected in the ASA status. 
Patients ≥ 70 had a higher frequency of an ASA status of 3 
(P = 0.034). No patients with an ASA status of 4 or 5 under-
went MVD.
Distribution of affected branches of the trigeminal nerve 
was similar. Median pain intensity before MVD was 7 on 
the NRS in both groups. The BNI Score was 4 and 5, in 
50% of patients respectively (no group difference, P = 0.845) 
(Table 2).
Before MVD, 97.1% of patients received oral medica-
tion, the most prevalent substance being carbamazepine. 
Four patients were not on oral medication due to severe 
side effects leading to discontinuation (4 patients < 70 and 
1 patient ≥ 70, P = 0.876).
Treatment details and safety analysis
Most patients underwent MVD as primary surgical treatment 
option (96.1% in patients < 70 versus 86.2% in patients ≥ 70, 
P = 0.036), while a small percentage received MVD after 
failed radiofrequency rhizotomy. The median length of sur-
gery and hospital stay was similar in both groups (Table 2).
Overall rates of transient neurological deficits were low in 
both groups, with transient mild facial hypoesthesia making 
up most of these deficits (23/139, 16.5%). Two patients < 70 
required surgical revision due to deep but extradural wound 
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infection. No other surgical revisions were required. The 
combined count of short-term neurological deficits and treat-
ment related complications was not different between groups 
(Table 3).
As to long-term neurological deficits, moderate postop-
erative hearing impairment occurred in 2 patients < 70 and 
1 patient ≥ 70. Facial hypoesthesia improved over time in all 
patients but a small area of permanent hypoesthesia persisted 
in 6 patients (4 patients < 70 and 2 patients ≥ 70). Persistent 
chronic headache after MVD was found in one patient of each 
group. One patient < 70 has persistent severe vertigo, incapaci-
tating the patient from engaging in gainful employment. The 
rate of persistent neurological deficits was not different for 
patients < 70 and patients ≥ 70 (Table 3). There was no treat-
ment related mortality.
Efficacy and long‑term follow‑up
Of all patients, 133 (95.7%) reported immediate pain relief 
after surgery with no significant difference between groups 
(P = 0.649) (Table 2).
The median follow-up for all patients was 25.2 months, 
with no significant difference between groups (Table 4).
At first follow-up after 3 months, 131 (94.2%) patients 
were pain free, with 19 of them still on a residual dose of 
anticonvulsant medication. Five patients (3.6%) had a good 
effect with occasional pain that did not reduce quality of 
Table 1  Patient demographics 
and comorbidities
Bold text indicates a statistically significant difference
Frequencies are presented as n (%). Age is presented as median and interquartile range
ASA American Society of Anesthesiologist grading system of operative fitness, TIA transient ischemic 
attack, GERD gastroesophageal reflux disease
Group  < 70 years  ≥ 70 years Overall P
N 103 36 139
Age (years) 57.6 [46.8–65.2] 73.4 [71.9–75.3] 63.4 [51.8–71.1]  < 0.001
Sex (females) 51 (49.5%) 17 (47.2%) 68 (48.9%) 0.813
ASA status 0.034
 1 6 (5.8%) – 6 (4.3%)
 2 82 (79.6%) 26 (72.2%) 108 (77.7%)
 3 15 (14.6%) 10 (27.8%) 25 (18%)
Comorbidities
 Headache syndrome 7 (6.8%) 2 (5.6%) 9 (6.5%) 0.795
 Surgery on sinuses 6 (5.8%) – 6 (4.3%) 0.139
 Fibromyalgia 4 (3.9%) – 4 (2.9%) 0.230
 Chronic sinusitis 1 (1.0%) – 1 (0.7%) 0.553
 Hypercholesterolemia 2 (1.9%) 7 (19.4%) 9 (6.5%) 0.001
 Arterial hypertension 32 (31.1%) 18 (50.0%) 50 (36.0%) 0.042
 Obstructive sleep apnea 5 (4.9%) 1 (2.8%) 6 (4.3%) 0.690
 Anticoagulation 2 (1.9%) 2 (5.6%) 4 (2.9%) 0.572
 Carotid stenosis 2 (1.9%) 6 (16.7%) 8 (5.8%) 0.004
 TIA in the past 3 (2.9%) 1 (2.8%) 4 (2.9%) 0.967
 Cardiac stents, aspirin 5 (4.9%) 7 (19.4%) 12 (8.6%) 0.013
 Diabetes mellitus type 2 4 (3.9%) 2 (5.6%) 6 (4.3%) 0.671
 Nicotine abuse 11 (10.7%) – 11 (7.9%) 0.066
 Von Willebrand disease 1 (1.0%) – 1 (0.7%) 1.000
 GERD 2 (1.9%) 2 (1.4%) 0.613
 Hypothyroidism 10 (9.7%) 8 (22.2%) 18 (12.9%) 0.080
 Depression 4 (3.9%) 0 (0%) 4 (2.9%) 0.572
 History of cancer 1 (1%) 6 (16.7%) 7 (5%) 0.001
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Table 2  Disease characteristics and treatment
Bold text indicates a statistically significant difference
Frequencies are presented as n (%). Symptom duration, pain intensity before MVD (NRS), average length of surgery and average length of stay 
are presented as median and interquartile range 
MVD microvascular decompression, NRS Numerical Rating Scale, BNI Score Barrow Neurological Institute Pain Intensity Score
Group  < 70 years  ≥ 70 years Overall P
N 103 36 139
Trigeminal branch affected 0.525
 II 26 (25.2%) 7 (19.4%) 33 (23.7%)
 III 14 (13.6%) 8 (22.2%) 22 (15.8%)
 I + II 7 (6.8%) 4 (11.1%) 11 (7.9%)
 II + III 42 (40.8%) 16 (44.4%) 58 (41.7%)
 I + II + III 14 (13.6%) 1 (2.8%) 15 (10.8%)
Side 0.401
 Left 45 (43.7%) 14 (38.9%) 59 (42.4%)
 Right 58 (56.3%) 22 (61.1%) 80 (57.6%)
Symptom duration before treatment (years) 4.0 [2.0–8.0] 4.5 [2.4–9.3] 4.0 [2.0–8.0] 0.442
Pain intensity before MVD, NRS 8 [7–8] 7 [7–8] 7 [7–8] 0.332
Pain intensity before MVD, BNI 0.845
 BNI Score 4 51 (49.5%) 19 (52.8%) 70 (50.4%)
 BNI Score 5 52 (50.5%) 17 (47.2%) 69 (49.6%)
MVD primary therapy 99 (96.1%) 31 (86.2%) 130 (93.5%) 0.036
MVD on recurrence after radiofrequency rhizotomy 4 (3.9%) 5 (13.8%) 9 (6.5%)
Average length of surgery (minutes) 165 [147–199] 173 [138–205] 168 [144–201] 0.579
Average length of stay (days) 8.3 [8.1–9.9] 9.1 [8.2–10.1] 8.4 [8.1–9.9] 0.225
Immediate pain relief after MVD 99 (96.1%) 34 (94.4%) 133 (95.7%) 0.649
Table 3  Complications and neurological deficits
Frequencies are presented as n (%)
SIADH syndrome of inappropriate antidiuretic hormone secretion, CSF Cerebrospinal fluid leak
Group  < 70 years  ≥ 70 years Overall P
N 103 36 139
Combined short-term complications and morbidities 22 (21.4%) 10 (27.8%) 32 (23.0%) 0.431
 Transient facial numbness 16 (15.5%) 7 (19.4%) 23 (16.5%)
 Transient trochlear nerve palsy – 1 (2.8%) 1 (0.7%)
 Transient vocal cord palsy – 1 (2.8%) 1 (0.7%)
 Transient facial palsy after ischemia in the facial motor nucleus – 1 (2.8%) 1 (0.7%)
 Venous sinus thrombosis with prolonged anticoagulation 1 (1%) – 1 (0.7%)
 Cerebellar ischemia, prolonged SIADH 1 (1%) – 1 (0.7%)
 CSF leak, lumbar drain 2 (1.9%) – 2 (1.4%)
 Wound infection requiring surgical revision 2 (1.9%) – 2 (1.4%)
 Surgical revision for other reasons – – –
Combined persistent deficits 8 (7.8%) 4 (11.1%) 12 (8.6%) 0.539
 Persistent chronic headache 1 (1.0%) 1 (2.8%) 2 (1.4%)
 Persistent severe vertigo 1 (1.0%) – 1 (0.7%)
 Persistent hearing impairment 2 (1.9%) 1 (2.8%) 3 (2.2%)
 Persistent facial hypesthesia 4 (3.9%) 2 (5.6%) 6 (4.3%)
Treatment-related mortality – – – 1.000
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life and did not require medication (equaling BNI Score 2). 
These patients were not counted as early recurrence. There 
were 3 patients (2 patients < 70 and 1 patient ≥ 70), that 
reported some pain, not adequately controlled with medica-
tions (BNI Score 4). The distribution of pain-control at first 
follow-up was similar between groups (Table 4).
For long term analysis of pain control, only patients with 
a minimum of 12 months follow-up were analyzed. The 
median follow-up was 44.6 months and patients ≥ 70 had 
a longer follow-up (40.2 versus 58.5 months, P = 0.014). 
Within the follow-up period, there was a tendency towards 
higher recurrence in patients < 70 (13, 17.6%) compared to 
patients ≥ 70 (8, 28.6%) but the difference was not significant 
(P = 0.274). Five patients suffered from severe recurrent TN, 
equal to a BNI Score of 5. Pain-control and severity of recur-
rent TN, as measured by the BNI Score was similar between 
patients < 70 and ≥ 70 (P = 0.897). Recurrences were man-
aged surgically by radiofrequency rhizotomy in 12 (11.8%) 
cases and medically in 9 (8.8%) cases (P = 0.431). There was 
a tendency towards earlier recurrence in patients ≥ 70 with-
out statistically significant differences for both median time 
to recurrence (P = 0.558, Table 4) and Kaplan–Meier based 
median pain-free interval (P = 0.391, Fig. 2 and Table 4). 
Of 81 (79.4%) patients without recurrent TN at the latest 
follow-up visit, 79 (97.5%) were pain-free while 2 patients 
suffered from persistent TN inadequately controlled with 
medication (Table 4).
Table 4  Short- and long-term follow-up
Bold text indicates a statistically significant difference
Frequencies are presented as n (%). Length of follow-up and time to recurrence are presented as median and interquartile range. Pain-free inter-
val is the result of Kaplan–Meier-Analysis and is presented as median and upper/lower boundaries of the 95% confidence interval
BNI Score Barrow Neurological Institute Pain Intensity Score, RF radiofrequency rhizotomy
Group  < 70 years  ≥ 70 years Overall P
All patients, N 103 36 139
 Length of follow-up (months) 24.0 [4.2–45.8] 34.4 [8.2–71.4] 25.2 [6.0–47.2] 0.066
 Pain intensity first follow-up 0.579
  BNI Score 1 81 (78.6%) 31 (86.1%) 112 (80.6%)
  BNI Score 2 5 (4.9%) 0 (0%) 5 (3.6%)
  BNI Score 3 15 (14.6%) 4 (11.1%) 19 (13.7%)
  BNI Score 4 2 (1.9%) 1 (2.8%) 3 (2.2%)
  BNI Score 5 – – –
Patients with ≥ 12 months follow-up, N 74 28 102
 Length of follow-up (months) 40.2 [22.7–64.1] 58.5 [36.2–81.9] 44.6 [26.7–72.3] 0.014
 Recurrence 13 (17.6%) 8 (28.6%) 21 (20.6%) 0.274
 Time to recurrence (months) 24.0 [15.5–28.4] 13.5 [7.7–38.4] 23.4 [9.5–28.4] 0.558
 Pain intensity upon recurrence 0.897
  BNI Score 1 – – –
  BNI Score 2 1 (7.7%) – 1 (4.8%)
  BNI Score 3 3 (23.1%) 2 (25%) 5 (23.8%)
  BNI Score 4 5 (38.5%) 5 (62.5%) 10 (47.6%)
  BNI Score 5 4 (30.8%) 1 (12.5%) 5 (23.8%)
 Management of recurrence 0.431
 Surgically (RF) 7 (9.5%) 5 (17.9%) 12 (11.8%)
 Medically 6 (8.1%) 3 (10.7%) 9 (8.8%)
 Pain intensity in non-recurrent patients (last follow-up) 0.350
  BNI Score 1 54 (88.5%) 18 (90%) 72 (88.9%)
  BNI Score 2 – – –
  BNI Score 3 6 (9.8%) 1 (5%) 7 (8.6%)
  BNI Score 4 1 (1.6%) 0 (0%) 1 (1.2%)
  BNI Score 5 0 (0%) 1 (5%) 1 (1.2%)
 Pain-free interval (months) (Kaplan–Meier analysis) 78.7 [70.9, 86.6] 73.5 [59.6, 87.4] 78.5 [71.4, 85.6] 0.391
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Risk factor analysis for recurrent trigeminal 
neuralgia
Univariate analyses for factors associated with recurrence of 
TN included demographic factors, comorbidities, treatment 
modalities, number of medications, pre- and postoperative 
pain intensity as well as postoperative neurological deficits.
There was a higher recurrence rate in patients with longer 
symptom duration before MVD, with a median symptom 
duration between patients with recurrence and non-recurrence 
of 3 years versus 7 years (P = 0.006). TN not responsive to 
medication before MVD, equaling BNI Score 5 (P = 0.049), 
was also associated with a higher recurrence rate. Other 
parameters were not associated with a higher recurrence rate 
in univariate analysis.
For multivariate analysis, binary logistic regression was 
performed with the two variables proven to be associated to 
recurrence in univariate analysis (symptom duration and BNI 
Score) as well as with the variables age and ASA status. None 
of these variables proved as independent factor associated with 
a higher risk for TN recurrence after MVD (Table 5).
Discussion
In this cross-sectional study, patients with TN above and 
below age 70 were compared regarding efficacy and safety 
of MVD. Patients ≥ 70 showed a significantly higher num-
ber of comorbidities and a higher proportion of preopera-
tive ASA 3 status. Albeit the higher age and the higher 
number of comorbidities, no significant difference in treat-
ment associated complications, permanent neurological 
deficits and—most importantly—in number of recurrences 
nor in the pain-free interval was shown (Fig. 2).
In terms of demographic factors patients were compara-
ble to other studies [16, 31]. The reported rate of immedi-
ate pain relief—usually 80–95% in the literature [32, 41], 
and of recurrence rates—reported between 5 and 30% in 
the literature [5, 6, 22, 35], were comparable to the results 
of the present study, where we showed 95.7% immediate 
pain relief and a recurrence rate of 20.6%.
The most frequently occurring neurological deficit in 
our study was facial hypoesthesia, with most cases resolv-
ing completely. In 6 cases (4.3%), a small patch of facial 
mild hypoesthesia persisted, a rate that compares favorably 
to the literature [5, 36].
One large study found symptom duration to be posi-
tively correlated to TN recurrence [5], a finding that was 
recapitulated in this series. However, it failed to remain an 
independent risk factor in multivariate analysis. Consistent 
with this finding, it was previously shown that microstruc-
tural changes in the trigeminal nerve, as determined by dif-
fusion tensor imaging MRI, are independent of symptom 
duration [25].
Most studies did not report detailed comorbidities or 
ASA status [16, 28, 33], and one study only included 
elderly patients with an ASA 1 and 2 status [3]. By con-
trast, almost 30% of patients ≥ 70 in our study were clas-
sified as ASA 3. Albeit the clear gap in comorbidities 
between age groups, we report no difference in postopera-
tive complications or permanent neurological deficits. The 
difference in comorbidities between groups thereby does 
not represent a limitation but a prerequisite to draw ade-
quate conclusions. One large retrospective study analyzing 
Fig. 2  Kaplan–Meier curve of the cumulative probability of non-
recurrence of trigeminal neuralgia. The cumulative probability of 
non-recurrence is (analogously to cumulative survival in studies 
with death as endpoint) the probability of non-recurrence of trigemi-
nal neuralgia at a certain postoperative day multiplied by the prob-
ability of having no recurrence in the previous postoperative period. 
It did not differ between patients < 70 and patients ≥ 70 years of age 
(P = 0.391)
Table 5  Multivariate analysis
BNI Score Barrow Neurological Institute Pain Intensity Score, ASA 
American society of anesthesiologist grading system of operative fit-
ness
Variable P Odds ratio 95% 
Confidence 
interval
Symptom duration 0.430 1.06 [0.92–1.23]
BNI Score 0.322 1.46 [0.69–3.09]
Age 0.173 0.96 [0.91–1.02]
ASA status 0.803 0.77 [0.10–5.77]
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data from 3273 patients out of a nationwide database 
showed that procedure-related mortality increased with 
age with a mortality rate of 1.2% for patients over 75 years. 
However, no data for preoperative comorbidities of any 
kind nor ASA status was included in that analysis and 
there was no report on outcome [31].
Another important factor presented here is the 
Kaplan–Meier based pain-free interval analysis which 
previous studies lack [16, 18, 28, 31, 33]. We were able to 
show that not only the number of recurrences, but also the 
pain-free interval is similar between patients above and 
below the age of 70. This is a crucial finding since a longer 
pain-free interval directly translates into less disability, 
depression and anxiety, all of which have been unequivo-
cally linked to TN [40].
Discussing alternative surgical treatment options, a large 
meta-analysis with 2163 patients showed that MVD had a 
lower number of recurrences compared to radiofrequency 
rhizotomy, reducing the risk by around 66% [24]. Other 
groups also showed that while pain control ranges at around 
80% for MVD over the course of 10 years [32, 41], there 
were almost 30% recurrences after 3 years for radiofre-
quency rhizotomy throughout all age groups [27, 38].
The superior long-term outcome of MVD over sympto-
matic surgical treatment options underscores the favorable 
risk profile in the older patient cohort and provides another 
strong argument for MVD as a primary surgical treatment 
option.
Our study stands out due to its cross-sectional design 
since long-term outcome was only evaluated in patients 
who were followed-up within the last 4 weeks. In contrast, 
previous studies evaluated patients during routine visits but 
not in a cross-sectional sense at a recent time point [18, 33].
There are two main limitations to our study. First, the 
small sample size of patients ≥ 70 might render subgroup 
analysis less robust, especially in binary logistic regression 
modelling. Second, a selection bias inevitably occurs since 
patients ≥ 70 with severe contraindications to major intracra-
nial surgery were directed towards radiofrequency rhizotomy 
or stereotactic radiosurgery. This must be considered when 
counseling patients towards the right treatment.
Despite these limitations, this study offers convincing 
new aspects that substantiate the justification of MVD in 
elderly patients.
Conclusion
In this study on the controversial topic of MVD in elderly 
patients with trigeminal neuralgia, we analyzed cohorts 
above and below 70 years of age with regard to efficacy and 
safety of MVD. We showed that MVD is equally safe and 
efficient despite a higher number of comorbidities in elderly 
patients. There was no significant difference in immediate 
and long-term pain relief between age groups and recurrence 
rates compared favorably to reports on symptomatic surgi-
cal treatments such as radiofrequency rhizotomy. The rel-
evance and novelty of our findings lies in the cross-sectional 
study design, the higher proportion of relevant preoperative 
comorbidities in the older age group and the Kaplan–Meier 
based analysis of the pain-free interval. Our study endorses 
MVD as routine surgical procedure for TN in elderly people 
as long as major contraindications to intracranial surgery 
are ruled out.
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